REGAL PARTNERS (01575): Proposed Adoption of New Share Option Scheme and Conditional Grant of Share Options
Regal Partners (01575) announced that, as the 2016 Share Option Scheme is about to expire, on 16 November 2026, the Board resolved to propose, in accordance with Chapter 17 of the Listing Rules, the adoption of a new share option scheme at an extraordinary general meeting, to provide incentives or rewards to participants for their contribution or potential contribution to the growth and development of the Group.
REGAL PARTNERS (01575) announced that, as the 2016 Share Option Scheme is due to expire, on 16 November 2026, the Board resolved to propose the adoption of a new share option scheme at an extraordinary general meeting in accordance with Chapter 17 of the Listing Rules, in order to provide incentives or rewards to participants for their contribution or potential contribution to the growth and development of the Group.
On the date of grant (i.e. 16 November 2026), under the new share option scheme, the Company conditionally granted conditional share options to the conditional grantee (i.e. Mr. Bai Yu, who was appointed as an executive director on the same date) to subscribe for a total of 38.6 million shares, subject to acceptance by the conditional grantee.
Related Articles

BAIGE DIGITAL (02672) is taking steps to initiate legal proceedings in the relevant Chinese courts against the relevant persons and/or entities in respect of the relevant matters.

US Stock Market Move | Optical communication concept stocks fall broadly in pre-market trading; POET Technologies (POET.US) drops over 8%.

INNOVENT BIO (01801) partner OLLIN BIOSCIENCES and its next-generation ophthalmology pipeline are to be acquired
BAIGE DIGITAL (02672) is taking steps to initiate legal proceedings in the relevant Chinese courts against the relevant persons and/or entities in respect of the relevant matters.

US Stock Market Move | Optical communication concept stocks fall broadly in pre-market trading; POET Technologies (POET.US) drops over 8%.

INNOVENT BIO (01801) partner OLLIN BIOSCIENCES and its next-generation ophthalmology pipeline are to be acquired






